Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Assembly Biosciences, Inc is a biotechnology business based in the US. Assembly Biosciences shares (ASMB) are listed on the NASDAQ and all prices are listed in US Dollars. Assembly Biosciences employs 140 staff and has a trailing 12-month revenue of around USD$82.8 million.
|52-week range||USD$5.18 - USD$27.84|
|50-day moving average||USD$6.0444|
|200-day moving average||USD$11.5082|
|Wall St. target price||USD$18.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.664|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$82.8 million|
|Gross profit TTM||USD$-69,794,000|
|Return on assets TTM||-12.3%|
|Return on equity TTM||-23.33%|
|Market capitalisation||USD$180.3 million|
TTM: trailing 12 months
There are currently 2.4 million Assembly Biosciences shares held short by investors – that's known as Assembly Biosciences's "short interest". This figure is 8.4% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting Assembly Biosciences shares can be evaluated.
Assembly Biosciences's "short interest ratio" (SIR) is the quantity of Assembly Biosciences shares currently shorted divided by the average quantity of Assembly Biosciences shares traded daily (recently around 824559.8615917). Assembly Biosciences's SIR currently stands at 2.89. In other words for every 100,000 Assembly Biosciences shares traded daily on the market, roughly 2890 shares are currently held short.
However Assembly Biosciences's short interest can also be evaluated against the total number of Assembly Biosciences shares, or, against the total number of tradable Assembly Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Assembly Biosciences's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Assembly Biosciences shares in existence, roughly 70 shares are currently held short) or 0.0746% of the tradable shares (for every 100,000 tradable Assembly Biosciences shares, roughly 75 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Assembly Biosciences.
Find out more about how you can short Assembly Biosciences stock.
We're not expecting Assembly Biosciences to pay a dividend over the next 12 months.
Assembly Biosciences's shares were split on a 1:5 basis on 14 July 2014. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assembly Biosciences shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Assembly Biosciences shares which in turn could have impacted Assembly Biosciences's share price.
Over the last 12 months, Assembly Biosciences's shares have ranged in value from as little as $5.18 up to $27.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assembly Biosciences's is 0.4306. This would suggest that Assembly Biosciences's shares are less volatile than average (for this exchange).
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs; and a collaboration and option agreement with Door Pharmaceuticals, LLC focused on the development of a hepatitis B virus core protein modulators. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.